Literature DB >> 24173652

Histological assessment of therapeutic response in breast cancer.

Rie Horii1, Futoshi Akiyama2.   

Abstract

Histological assessment of the therapeutic response to neoadjuvant therapy gives us information regarding the efficacy of a given treatment in individual patients. Such information is useful for guiding selection of appropriate therapeutic strategies after surgery. In many studies of neoadjuvant chemotherapy (NAC) for breast cancer, both the histological therapeutic effect in the primary lesion and the lymph node metastatic status are significantly related to prognosis. The histological assessment of therapeutic response helps determine prognosis in breast cancer treated with NAC; however, methodological problems remain. There are many different histological criteria currently used to assess therapeutic response. Even when the same criteria are used, use of different methods for examination of surgical material can cause different results for the same patient case. When histological therapeutic effect is determined in daily clinical practice, pathologists have to describe the criteria used and their examination methods. Histological criteria for evaluation of therapeutic response and methods for examination of surgical materials after neoadjuvant therapy must be standardized in the near future.

Entities:  

Keywords:  Breast cancer; Histological assessment of therapeutic response; Neoadjuvant therapy; Pathology

Mesh:

Substances:

Year:  2013        PMID: 24173652     DOI: 10.1007/s12282-013-0499-6

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  4 in total

1.  Hysterectomy for Recurrent/Residual Cervical Cancer Following Definitive Radiotherapy.

Authors:  Tadaharu Nakasone; Yusuke Taira; Yuko Shimoji; Yoshihisa Arakaki; Tomoko Nakamoto; Takuma Ooyama; Wataru Kudaka; Itomi Kaneshima; Kumiko Nishihira; Keiko Mekaru; Yoichi Aoki
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.

Authors:  Manabu Futamura; Yasuko Nagao; Kazuhiro Ishihara; Makoto Takeuchi; Takumi Nakada; Yoshihiro Kawaguchi; Masayoshi Asano; Iwao Kumazawa; Takashi Shiroko; Kasumi Morimitsu; Ryutaro Mori; Masahito Nawa; Toshio Shimokawa; Kazuhiro Yoshida
Journal:  Breast Cancer       Date:  2017-01-03       Impact factor: 4.239

Review 3.  Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Huan Wang; Xiaoyun Mao
Journal:  Drug Des Devel Ther       Date:  2020-06-18       Impact factor: 4.162

4.  L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism.

Authors:  Miku Sato; Narumi Harada-Shoji; Takafumi Toyohara; Tomoyoshi Soga; Masatoshi Itoh; Minoru Miyashita; Hiroshi Tada; Masakazu Amari; Naohiko Anzai; Shozo Furumoto; Takaaki Abe; Takashi Suzuki; Takanori Ishida; Hironobu Sasano
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.